Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...

Acres Farms, the vertical farming startup headquartered in Hamilton, announced Monday, Feb. 10, capital raises last year ...

US-based pharmaceutical company Moleculin Biotech has received approval from Ukraine's Ministry of Health to begin enrolment in its Phase III trial of annamycin with cytarabine for treating acute ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

LOWELL — After suffering a pair of two-goal losses to the Toronto Sceptres this season, the Boston Fleet got their revenge on Wednesday night. Boston scored twice in the first period and held on ...

Copyright 2025 The Associated Press. All Rights Reserved. Share LOWELL, Mass. (AP) — Alina Müller and Emily Brown each scored their first goal of the season in the ...

Key recommendations for policymakers and businesses. Jan 22, 2025 21:57 JSW UAV to Set Up Rs 800 Crore Facility in Telangana JSW UAV Ltd. has signed an MoU with the Telangana government to establish a ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...